Jim Stephanou is a visionary leader who recently assumed the role of IPS CEO after dedicating more than 35 years of his career to various operating companies, including Merck and Bayer. He is recognized as an industry leader in innovative and efficient project delivery methods because of his unwavering commitment to delivering capital programs in the most successful and effective manner. As CEO of IPS, Jim is focused on pushing the boundaries of innovation in the architectural, engineering, and construction (AEC) industry, specifically as it relates to the life sciences market. As Jim often states, “patients are waiting,” and IPS’ role is to help their clients develop, manufacture, and accelerate the delivery of life-impacting medicines, ultimately improving the quality of life or saving the lives of millions around the world.